Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
Phase 3
Completed
- Conditions
- Primary Immunoglobulin a Nephropathy (IgAN)
- Interventions
- Drug: Nefecon
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT05534919
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older
Phase 3
Not yet recruiting
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: PTX-COVID19-BBiological: Vaxzevria®
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05534035
Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older
Phase 3
Not yet recruiting
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: PTX-COVID19-BBiological: Comirnaty®
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
- Target Recruit Count
- 3800
- Registration Number
- NCT05534048
© Copyright 2025. All Rights Reserved by MedPath